Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2007 1
2008 1
2009 4
2011 3
2012 2
2013 3
2014 5
2015 5
2016 2
2017 5
2018 2
2019 4
2020 9
2021 10
2022 10
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, Llarena C. Meca-Lallana JE, et al. Among authors: casanova b. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. Neurol Ther. 2023. PMID: 37861931 Free PMC article.
Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
Ribes García S, Castillo-Villalba J, Gasque Rubio R, Carratalà Boscà S, Cubas-Nuñez L, Alcalá C, Pérez-Miralles FC, Bonaventura CE. Ribes García S, et al. Among authors: bonaventura ce. Mult Scler Relat Disord. 2023 Nov;79:105033. doi: 10.1016/j.msard.2023.105033. Epub 2023 Sep 29. Mult Scler Relat Disord. 2023. PMID: 37832257
Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
Tortosa-Carreres J, Quiroga-Varela A, Castillo-Villalba J, Piqueras-Rodríguez M, Ramió-Torrenta L, Cubas-Núñez L, Gasqué-Rubio R, Quintanilla-Bordas C, Huertas-Pons JM, Miguela A, Casanova B, Laiz-Marro B, Pérez-Miralles FC. Tortosa-Carreres J, et al. Among authors: casanova b. Mult Scler Relat Disord. 2023 Nov;79:104997. doi: 10.1016/j.msard.2023.104997. Epub 2023 Sep 9. Mult Scler Relat Disord. 2023. PMID: 37714099
Eculizumab for a catastrophic relapse in NMOSD: case report.
Gorriz D, Pérez-Miralles FC, Quintanilla-Bordás C, Alcalá C, Frasquet M, Casanova B. Gorriz D, et al. Among authors: casanova b. Neurol Sci. 2024 Jan;45(1):249-251. doi: 10.1007/s10072-023-06971-x. Epub 2023 Jul 27. Neurol Sci. 2024. PMID: 37500991
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Gascón-Giménez F, Alcalá C, Ramió-Torrentà L, Montero P, Matías-Guiu J, Gómez-Estevez I, Oreja-Guevara C, Gil-Perotín S, Blanco Y, Carcelén M, Quintanilla-Bordás C, Costa L, Villar LM, Martínez-Rodriguez JE, Domínguez JA, Calles C, González I, Sotoca J, Oterino A, Lucas-Jimenez C, Pérez-Miralles F, Casanova B. Gascón-Giménez F, et al. Among authors: casanova b. Front Neurol. 2023 Mar 7;14:1060696. doi: 10.3389/fneur.2023.1060696. eCollection 2023. Front Neurol. 2023. PMID: 36959824 Free PMC article.
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal E, Fernández-Velasco JI, García-Sánchez MI, Sainz de la Maza S, Llufriu S, Álvarez-Lafuente R, Casanova B, Comabella M, Ramió-Torrentà L, Martínez-Rodríguez JE, Brieva L, Saiz A, Eichau S, Cabrera-Maqueda JM, Villarrubia N, Espiño M, Pérez-Miralles F, Montalbán X, Tintoré M, Quiroga-Varela A, Domínguez-Mozo MI, Rodríguez-Jorge F, Chico-García JL, Lourido D, Álvarez-Cermeño JC, Masjuan J, Costa-Frossard L, Villar LM. Monreal E, et al. Among authors: casanova b. JAMA Neurol. 2023 Apr 1;80(4):397-403. doi: 10.1001/jamaneurol.2023.0010. JAMA Neurol. 2023. PMID: 36848127 Free PMC article.
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.
Muñoz-San Martín M, Gómez I, Quiroga-Varela A, Gonzalez-Del Río M, Robles Cedeño R, Álvarez G, Buxó M, Miguela A, Villar LM, Castillo-Villalba J, Casanova B, Quintana E, Ramió-Torrentà L. Muñoz-San Martín M, et al. Among authors: casanova b. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 9;10(1):e200069. doi: 10.1212/NXI.0000000000200069. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36724195 Free PMC article.
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.
Alcalá Vicente C, Lacruz L, Gascón F, Carratalà S, Quintanilla-Bordás C, Sanz MT, Carcelén-Gadea M, Mallada J, Carreres J, Gabaldón Torres L, Dominguez JA, Cañizares E, Gil-Perotin S, Cubas L, Gasqué Rubio R, Castillo-Villalba J, Pérez-Miralles FC, Casanova B. Alcalá Vicente C, et al. Among authors: casanova b. Front Neurol. 2022 Oct 28;13:991596. doi: 10.3389/fneur.2022.991596. eCollection 2022. Front Neurol. 2022. PMID: 36388220 Free PMC article.
Oligoclonal M bands unveil occult inflammation in multiple sclerosis.
Casanova B, Castillo J, Quintanilla-Bordás C, Sanz MT, Fernández-Velasco JI, Alcalá C, Carratalá S, Gasque R, Rubio A, Cubas L, Villar LM, Pérez-Miralles F. Casanova B, et al. Mult Scler Relat Disord. 2022 Dec;68:104118. doi: 10.1016/j.msard.2022.104118. Epub 2022 Aug 15. Mult Scler Relat Disord. 2022. PMID: 36057174
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
69 results